Efficacy and safety of oral antiviral therapy medications in the treatment of moderate and severe cases of COVID-19. Results of a comparative retrospective observational study

The aim of the study was to compare the clinical efficacy and safety of two antiviral therapy medications that suppress viral replication (viral RNA polymerase inhibitors) in the treatment of patients with COVID-19: favipiravir and riamilovir.

Material and methods. Clinical efficacy and safety were assessed based on a retrospective study of 1071 patients, including 561 patients who received favipiravir and 510 patients who received riamilovir.

Results. A statistically significant reduction in the duration of symptoms and average hospital days was recorded among patients who received ramilovir in both moderate and severe forms of the disease compared with the group that received favipiravir. Inflammatory markers (CRP, fibrinogen) decreased faster in the riamilovir group.

Conclusion. Riamilovir has demonstrated higher levels of clinical efficacy and safety in the treatment of COVID-19 compared to favipiravir.

1. Кошерова Б.Н., Бегайдарова Р.Х., Алшынбекова Г.К. и др. Сравнительный анализ лекарственных препаратов, используемых в мире и в Республике Казахстан для лечения COVID 19. Современные проблемы науки и образования. 2021; (1). URL: https://science-education.ru/ru/article/view?id=30507 (дата обращения: 22.12.2023).

2. Balykova L.A., Pavelkina V.F., Shmyreva N.V., et al. EFFICACY and safety of some etiotropic therapeutic schemes for treating patients with novel coronavirus infection (COVID-19). Pharmacy & Pharmacology. 2020; 8 (3): 150–159. https://doi.org/10.19163/2307-9266-2020-8-3-150-159. (in Russian)]

3. Balykova L.A., Govorov A.V., Vasilyev A.O., et al. Characteristics of COVID-19 and possibilities of early causal therapy. Results of favipiravir use in clinical practice. Infekc. bolezni (Infectious diseases). 2020; 18 (2): 30–40. doi: https://doi.org/10.20953/1729-9225-2020-3-30-40. (in Russian)]

4. Leonova M.V. Favipiravir as a potential countermeasure for COVID-19. Consilium Medicum. 2020; 22 (11): 56–60. doi: https://doi.org/10.26442/20751753.2020.11.200368. (in Russian)]

5. Zykov K.A., Sinitsyn E.A., Rvacheva A.V., Bogatyreva A.O., Zykova A.A., Shapovalenko T.V. Rationale for a new outpatient drug therapy algorithm in COVID-19 patients based on the principle of «Multi-hit» approach. Antibiot Khimioter = Antibiotics and Chemotherapy. 2021; 66 (3–4): 49–61. doi: https://doi.org/10.37489/0235-2990-2021-66-3-4-49-61. (in Russian)]

6. Sabitov A.U., Belousov V.V., Edin A.S., et al. Practical experience of using Riamilovir in treatment of patients with moderate COVID-19. Antibiot Khimioter = Antibiotics and Chemotherapy. 2020; 65 (7–8): 27–30. doi: https://doi.org/10.37489/0235-2990-2020-65-7-8-27-30. (in Russian)]

7. Sabitov А.U., Sorokin Р.V., Dashutina S.U. The efficacy and safety of Riamilovir in the treatment of patients with COVID-19. 2021; 66: 1–2: 33–37. Antibiot Khimioter = Antibiotics and Chemotherapy. doi: https://doi.org/10.37489/0235-2990-2021-66-1-2-33-37. (in Russian)]

8. Kasyanenko K.V., Maltsev O.V., Kozlov K.V., et al. Clinical efficiency and safety of Riamilovir for treating patients with SARS-CoV-2 infection. Antibiot Khimioter = Antibiotics and Chemotherapy. 2020; 65 (11–12): 16–21. doi: https://doi.org/10.37489/0235-2990-2020-65-11-12-16-21. (in Russian)]

9. Chuhliaev P.V., Janibekov J.J., Khavkina D.A., Ruzhentsova T.A. Efficacy and safety of etiotropic antiviral therapy in COVID 19 in outpatient patients. Medical Alphabet. 2022; (14): 23–26. doi: https://doi.org/10.33667/2078-5631-2022-18-23-26. (in Russian)]

10. Kasyanenko K.V., Kozlov K.V., Maltsev O.V., Lapikov I.I., et al. Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19. Terapevticheskii Arkhiv. 2021; 93 (3): 290–294. doi: https://doi.org/10.26442/00403660.2021.03.200719. (in Russian)]

11. Erez A., Shental O., Tchebiner J.Z., et al. Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients. Isr Med Assoc J. 2014; 16 (7): 439–443.

12. Kiselev Yu.Yu., Matveev A.V., Mirzaev K.B., Sychev D.A. Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020; (4S): 115–119. doi: https://doi.org/10.37489/2588-0519-2020-S4-115-119. (in Russian)]

13. Zhirnov O.P., Chernyshova A.I. Favipiravir: the hidden threat of mutagenic action. Journal of Microbiology, Epidemiology and Immunobiology = Zhurnal Mikrobiologii, Èpidemiologii i Immunobiologii. 2021; 98 (2): 213–220. doi: https://doi.org/10.36233/0372-9311-114. (in Russian)]